Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Concert Pharmaceuticals and Celgene Corporation have entered into strategic collaboration to direct deuterium-modified compounds targeting cancer and inflammation.
Subscribe to our email newsletter
Initially, the collaboration will focus on one program, but has the potential to encompass multiple targets.
As per the agreement, Concert will receive an upfront payment of more than $300m from Celgene for the development, regulatory and sales milestone development.
In addition, Concert will receive tiered royalties on any product sales for each of the programs advanced by Celgene.
Concert Pharmaceuticals president and CEO Roger Tung said, "We look forward to working with Celgene to evaluate the potential benefits of deuterium-modification for a number of programs emerging in our pipeline."